Sales & Marketing News | pharmaphorum

News

EVERSANA taps Adobe Firefly in quest to ‘pharmatise’ GenAI

EVERSANA has taken another step forwards in its effort to put generative artificial intelligence (GenAI) at the heart of the pharma industry’s processes.

News

'Landmark' deal reached on UK voluntary rebate scheme

After months of wrangling, an agreement has finally been reached on a successor to the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), the system of reve

News

After FDA no, Almirall’s eczema drug gets EU okay

The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in

News

Lilly to invest $2.5bn for obesity, diabetes drug production

Eli Lilly has followed Novo Nordisk in announcing a big investment in its manufacturing network, intended to meet anticipated strong future demand for diabetes and obesity

News

Xtandi cleared by FDA for earlier-stage prostate cancer

Already a mainstay of prostate cancer therapy, Pfizer and Astellas’ Xtandi has picked up a new approval in the US that could reinvigorate the drug, even as it approaches i

News

FDA’s Janet Woodcock will step down early next year

Janet Woodcock will bring a career at the FDA spanning almost four decades to a close next year, retiring from her current role as principal deputy commissioner of the reg

EVERSANA taps Adobe Firefly in quest to ‘pharmatise’ GenAI

'Landmark' deal reached on UK voluntary rebate scheme

After FDA no, Almirall’s eczema drug gets EU okay

Lilly to invest $2.5bn for obesity, diabetes drug production

Xtandi cleared by FDA for earlier-stage prostate cancer

FDA’s Janet Woodcock will step down early next year

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks